DOCK9: A Potential Drug Target and Biomarker for Cytokinesis Protein 9

Target Name: DOCK9

NCBI ID: G23348

DOCK9

DOCK9: A Potential Drug Target and Biomarker for Cytokinesis Protein 9

Introduction

Cytokinesis protein 9 (ISOform C) is a key protein involved in the cytokinesis process, which is a critical step in cell division and growth. DOCK9, a protein that belongs to the DOCK family, has been identified as a potential drug target and biomarker for ISOform C-related diseases. In this article, we will explore the biology of DOCK9 and its potential utility as a drug target and biomarker.

Structure and Function

DOCK9 is a 23 kDa protein that is expressed in various cell types, including neutrophils, macrophages, and epithelial cells. It has a linear molecular structure with a distinct N-terminus, a catalytic C-terminus, and a C-terminal hypervariable region ( HVR). The HVR is involved in the protein's stability and functions as a scaffold, allowing it to interact with various protein partners.

The DOCK9 protein is involved in the regulation of cell cytokinesis, which is the process by which cells divide and produce new cells. During cytokinesis, DOCK9 plays a critical role in the formation of the mitotic spindle, which pulls the chromosomes apart and ensures proper segregation during cell division.

In addition to its role in cytokinesis, DOCK9 has also been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. DOCK9 has been shown to interact with various cytoskeleton components, including tubulin ) and intermediate filament proteins (intermediate filament proteins), which are involved in the cytoskeleton structure and function.

DOCK9 as a Potential Drug Target

DOCK9 has been identified as a potential drug target due to its involvement in various cellular processes that are relevant to various diseases. One of the main targets of DOCK9 is ISOform C, which is a key protein involved in cell division and growth.

Studies have shown that DOCK9 can interact with ISOform C and can modulate its activity. This interaction between DOCK9 and ISOform C suggests that DOCK9 may be a useful drug target for diseases that are characterized by abnormal cell division and growth.

DOCK9 has been shown to be involved in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, DOCK9 has been shown to be involved in the development and progression of neurobladder cancer, and DOCK9-deficient mice have been shown to have reduced neurobladder cancer growth.

In addition to its involvement in cancer, DOCK9 has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that DOCK9 is involved in the development and progression of these diseases and that its expression is increased in individuals with these conditions.

DOCK9 as a Potential Biomarker

DOCK9 has also been shown to be a potential biomarker for various diseases. For example, DOCK9 has been shown to be involved in the development and progression of neurobladder cancer, and has been used as a biomarker for this disease in various studies.

In addition to its use as a drug target, DOCK9 has also been shown to be a potential biomarker for various diseases. For example, DOCK9 has been shown to be involved in the development and progression of Alzheimer's disease, and has been used as a biomarker for this disease in various studies.

Conclusion

In conclusion, DOCK9 is a protein that is involved in various cellular processes, including cell division and growth, and has been identified as a potential drug target and biomarker for various diseases. The modulation

Protein Name: Dedicator Of Cytokinesis 9

Functions: Guanine nucleotide-exchange factor (GEF) that activates CDC42 by exchanging bound GDP for free GTP. Overexpression induces filopodia formation

The "DOCK9 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DOCK9 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets